LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma

다국어 초록 (Multilingual Abstract)

Objective: To assess the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 treatment response algorithm (TRA) for the evaluation of hepatocellular carcinoma (HCC) treated with transarterial radioembolization.
Materials and Methods: This retrospective study included patients who underwent transarterial radioembolization for HCC followed by hepatic surgery between January 2011 and December 2019. The resected lesions were determined to have either complete (100%) or incomplete (< 100%) necrosis based on histopathology. Three radiologists independently reviewed the CT or MR images of pre- and post-treatment lesions and assigned categories based on the LI-RADS version 2018 and the TRA, respectively. Diagnostic performances of LI-RADS treatment response (LR-TR) viable and nonviable categories were assessed for each reader, using histopathology from hepatic surgeries as a reference standard. Inter-reader agreements were evaluated using Fleiss κ.
Results: A total of 27 patients (mean age ± standard deviation, 55.9 ± 9.1 years; 24 male) with 34 lesions (15 with complete necrosis and 19 with incomplete necrosis on histopathology) were included. To predict complete necrosis, the LR-TR nonviable category had a sensitivity of 73.3–80.0% and a specificity of 78.9–89.5%. For predicting incomplete necrosis, the LR-TR viable category had a sensitivity of 73.7–79.0% and a specificity of 93.3–100%. Five (14.7%) of 34 treated lesions were categorized as LR-TR equivocal by consensus, with two of the five lesions demonstrating incomplete necrosis. Interreader agreement for the LR-TR category was 0.81 (95% confidence interval: 0.66–0.96).
Conclusion: The LI-RADS version 2018 TRA can be used to predict the histopathologic viability of HCCs treated with transarterial radioembolization.

참고문헌 (Reference)

1 Min JH, "Vanishing washout of hepatocellular carcinoma according to the presence of hepatic steatosis: diagnostic performance of CT and MRI" 2020

2 Cools KS, "Validation of the liver imaging reporting and data system treatment response criteria after thermal ablation for hepatocellular carcinoma" 26 : 203-214, 2020

3 Sacco R, "Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives" 21 : 6518-6525, 2015

4 Landis JR, "The measurement of observer agreement for categorical data" 33 : 159-174, 1977

5 Chaudhry M, "The LI-RADS version 2018 MRI treatment response algorithm: evaluation of ablated hepatocellular carcinoma" 294 : 320-326, 2020

6 Sangro B, "Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation" 54 : 868-878, 2011

7 Kulik LM, "Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis" 47 : 71-81, 2008

8 Hilgard P, "Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival" 52 : 1741-1749, 2010

9 Kim HC, "Radioembolization for the treatment of hepatocellular carcinoma" 23 : 109-114, 2017

10 Salem R, "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes" 138 : 52-64, 2010

11 Sangro B, "Radioembolization for hepatocellular carcinoma" 56 : 464-473, 2012

12 Kloeckner R, "MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma" 33 : 532-540, 2010

13 Kim SW, "LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features" 30 : 2861-2870, 2020

14 Gervais DA, "LI-RADS treatment response algorithm:performance and diagnostic accuracy" 292 : 235-236, 2019

15 Shropshire EL, "LI-RADS treatment response algorithm: performance and diagnostic accuracy" 292 : 226-234, 2019

16 Semaan S, "Imaging of hepatocellular carcinoma response after 90Y radioembolization" 209 : W263-W276, 2017

17 Seo N, "Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017" 30 : 261-271, 2020

18 European Association for the Study of the Liver, "EASL clinical practice guidelines: management of hepatocellular carcinoma" 69 : 182-236, 2018

19 Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases" 68 : 723-750, 2018

20 Amorim J, "Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response" 45 : 3119-3128, 2020

21 American College of Radiology, "CT/MRI Liver Imaging Reporting and Data System version 2018"

22 Kim DH, "Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma" 71 : 534-542, 2019